Clinical Trials Logo
  1. Home
  2. Conjunctivitis, Allergic
  3. NCT01289431

Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis

Conjunctivitis, Allergic Clinical Trial

Official title:
Dose Ranging Study to Evaluate the Safety and Efficacy of Mapracorat Ophthalmic Formulation, in Subjects With Allergic Conjunctivitis Compared to Vehicle in a Conjunctival Allergen Challenge (CAC).

Clinical Trial Summary

The objective of this study is to evaluate the dose response, and efficacy of Mapracorat ophthalmic formulation compared to its vehicle for the prevention of symptoms and signs associated with allergic conjunctivitis using a conjunctival allergen challenge (CAC) model.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01289431
Study type Interventional
Source Bausch & Lomb Incorporated
Contact
Status Completed
Phase Phase 2
Start date February 2011
Completion date April 2011
View Details
See also
  Status Clinical Trial Phase
Completed NCT00501527 - Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense Phase 2
Completed NCT00422149 - Twin SUBLIVAC® Grasses Clinical Efficacy Study Phase 3
Completed NCT01470118 - A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Phase 4
Completed NCT03709121 - A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber Phase 1/Phase 2
Completed NCT02555761 - Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea
Completed NCT01732757 - A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Phase 4
Recruiting NCT04299399 - Corneal Biomechanical Changes of Allergic Conjunctivitis
Completed NCT00917488 - Glycyphagus Domesticus Allergen Extract. Determination of the in Vivo Biological Activity in Histamine Equivalent Units (HEP). Phase 2
Completed NCT03375775 - Evaluation of Subcutaneous Immunotherapy Towards Pollen in Children N/A
Completed NCT02082262 - AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis Phase 3
Withdrawn NCT01541904 - Efficacy and Safety of PRO-118 Ophthalmic Solution in Allergic Conjunctivitis Phase 2
Completed NCT00311844 - A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209) Phase 4
Completed NCT02161146 - AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis Phase 3
Completed NCT00718744 - Standardization of Chortoglyphus Arcuatus Allergenic Extract. Determination of Biological Activity in HEP Units Phase 2
Recruiting NCT03186755 - Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis Phase 4
Completed NCT01987765 - Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea N/A
Completed NCT06063044 - Food-specific IgG4-guided Elimination Diets Improve Allergy Symptoms in Children
Completed NCT00655109 - A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis Phase 4
Completed NCT00424398 - Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis Phase 2/Phase 3
Completed NCT03012165 - A Study of ADX-102 in Subjects With Allergic Conjunctivitis Phase 2